Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1712667

	registered interest
	date	22/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to (a) trial and (b) roll-out early cancer screening.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	22951
	answer	answer is ministerial correction date of answer 24/04/2024 answer text <p>In England, early cancer screening is already in place for cervical, breast, and bowel cancer. The UK National Screening Committee (UK NSC) does not currently recommend screening for prostate cancer due to the inaccuracy of the current best test, called Prostate Specific Antigen. We are providing £16 million of funding to Prostate Cancer UK's £42 million trial, which is aimed at helping us find a way of catching prostate cancer in men as early as possible. The UK NSC is also commissioning evidence for six possible approaches to targeted prostate screening for those at higher risk. The UK NSC will publish its recommendations when complete.</p><p>NHS England is responsible for the running of the Targeted Lung Health Check Programme, and its conversion to a nationally rolled out NHS Targeted Lung Cancer Screening Programme by 2030.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 24/04/2024 14:48:02 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4131 label Biography information for Jim Shannon

1701263

	registered interest
	date	16/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Semaglutide: Health Hazards
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to increase the public's awareness of the side effects that can arise from taking weight loss drugs such as Ozempic.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	21989
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) plays a pivotal role in ensuring the safety, efficacy, and quality of medicines and healthcare products available to patients in the United Kingdom. Patient safety remains the MHRA’s highest priority, and they take every opportunity to encourage reporting of any safety concerns to the Yellow Card scheme, which helps to improve the safe use of medicines and medical devices for everyone.</p><p>New medicines including, Mounjaro and Wegovy, are intensively monitored to ensure that any new safety concerns are identified promptly. The Commission on Human Medicines and the MHRA encourages the reporting of all suspected reactions to newer drugs and vaccines, which are denoted by an inverted Black Triangle symbol. This symbol appears next to the name of a relevant product in drug safety updates, the British National Formulary and the Nurse Prescribers’ Formulary, the monthly index of medical specialities, the electronic medicines compendium, and advertising material. Patient information leaflets accompanying licensed medicines in the UK must include a description of the adverse reactions which may occur in normal use of the medicinal product, as well as information on how to report them. All adverse reactions must be reflected in the leaflet, in language that the patient will understand.</p><p>The MHRA has received a small number of reports of falsified and unlicenced medicines being sold illegally online as a treatment for weight loss. The agency has issued public health messaging warning of the dangers of buying such medicines from illegal trading sources online.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 22/04/2024 11:07:07 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4131 label Biography information for Jim Shannon

1697030

	registered interest
	date	19/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Oral Cancer: Diagnosis
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what information his Department holds on the number of people diagnosed with mouth cancer in the last twelve months.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	19359
	answer	answer is ministerial correction date of answer 27/03/2024 answer text <p>The information requested is not available for the last twelve months. The most recent data available from 2021 shows 9,018 people were diagnosed with mouth cancer in England. Further information is available at the following link:</p><p><a href="https://digital.nhs.uk/data-and-information/publications/statistical/cancer-registration-statistics/england-2021---summary-counts-only" target="_blank">https://digital.nhs.uk/data-and-information/publications/statistical/cancer-registration-statistics/england-2021---summary-counts-only</a></p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 27/03/2024 10:13:35 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4131 label Biography information for Jim Shannon

1694454

	registered interest
	date	07/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what her expected timescale is for the availability of the Galleri blood test in cancer testing and diagnosis across the NHS.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	17545
	answer	answer is ministerial correction date of answer 13/03/2024 answer text <p>The NHS-Galleri trial is looking into the use of a new blood test to see if it can help the National Health Service to detect cancer early, when used alongside existing cancer screening. The trial recruited the target of 140,000 participants, and interim results are expected in spring or summer 2024.</p><p>If the trial is successful, the NHS has committed to rolling out up to one million Galleri tests in 2024 and 2025, as part of an interim implementation pilot. The clinical trial is currently planned to conclude in 2025, with results expected in 2026.</p><p>Should the final results be positive, the UK National Screening Committee (UK NSC) may consider the use of the test in a national screening programme. A UK NSC-recommended national screening programme would need to consider the effectiveness of the test, balancing the risk of false positives and unnecessary invasive treatments, against potential early detection.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 13/03/2024 15:09:07 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4131 label Biography information for Jim Shannon

1693749

	registered interest
	date	05/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Osteoporosis
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many over 25s have been diagnosed with osteoporosis in the last three years.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	17094
	answer	answer is ministerial correction date of answer 12/03/2024 answer text <p>The information is not collected in the format requested. However, the below table shows the number of finished admission episodes (FAEs) with a primary diagnosis of osteoporosis, for patients aged 25 years old and over in England, for the years 2020/21 to 2022/23:</p><table><tbody><tr><td><p>Year</p></td><td><p>FAEs</p></td></tr><tr><td><p>2020/21</p></td><td><p>32,552</p></td></tr><tr><td><p>2021/22</p></td><td><p>43,391</p></td></tr><tr><td><p>2022/23</p></td><td><p>47,015</p></td></tr></tbody></table><p>Source: Hospital Episode Statistics from NHS England.</p><p>Note: This data provides a proxy to show overall trends.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 12/03/2024 17:51:25 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4131 label Biography information for Jim Shannon

1693013

	registered interest
	date	01/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Bowel Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help ensure equality in bowel cancer outcomes.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	16467
	answer	answer is ministerial correction date of answer 07/03/2024 answer text <p>The National Health Service is taking several steps to improve bowel cancer outcomes for patients across England. The NHS is working towards its Long Term Plan’s ambition of diagnosing 75% of all stageable cancers at stage one and two, by 2028. Achieving this will mean that an additional 55,000 people each year will survive their cancer for at least five years after diagnosis.  With progress made on reducing waiting times, cancer is being diagnosed at an earlier stage more often, with survival rates improving across almost all types of cancer.</p><p> </p><p>In 2023, NHS England’s Help Us Help You campaign urged people to take up the offer of bowel screening when invited, while gradually extending the screening offer from those aged 60 down to 50 years old, ensuring more people are diagnosed with bowel cancer at the earliest stage.</p><p> </p><p>The NHS is also now offering routine preventative bowel cancer screening to thousands of people in England with a genetic condition, Lynch syndrome, that increases their chance of developing bowel cancer and certain other cancers. This gives the NHS a better chance of finding cancers at a time when they can be more easily and effectively treated.</p><p> </p><p>Tackling disparities is important in improving all types of cancer outcomes. The Government is committed to its levelling up mission, to narrow the gap in healthy life expectancy by 2030 and increase healthy life expectancy by five years by 2035. Our approach will continue to focus on supporting people to live healthier lives, helping the NHS and social care provide the best treatment and care for patients, and tackling health disparities through national and system interventions such as the NHS’s Core20PLUS5 programme.</p><p> </p><p>The Office for Health Improvement and Disparities was set up to address health inequalities with a range of interventions, including accelerating prevention programmes, reducing digital exclusion, supporting general practice in deprived communities, and improving health literacy.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 07/03/2024 13:58:23 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4131 label Biography information for Jim Shannon

1693014

	registered interest
	date	01/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Gastrointestinal Cancer: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to increase the number of patients with lower gastrointestinal cancers who receive their first treatment within 62 days of being urgently referred by their GP.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	16468
	answer	answer is ministerial correction date of answer 07/03/2024 answer text <p>The Department is taking steps to reduce cancer treatment waiting times across England, including the time between an urgent general practice referral and the commencement of treatment for cancer for patients. The Government is working jointly with NHS England on implementing the delivery plan for tackling the COVID-19 related backlogs in elective care, and plans to spend more than £8 billion from 2022/23 to 2024/25 to help drive up and protect elective activity, including cancer diagnosis and treatment.  Interventions include a pathway re-design to maximise capacity, including comprehensive faecal immunochemical test implementation to detect lower gastrointestinal cancers faster.</p><p>In the 2023/24 Operational Planning Guidance, NHS England announced that it is providing over £390 million in cancer service development funding to Cancer Alliances in each of the next two years, to support delivery of the strategy and the operational priorities for cancer, which includes increasing and prioritising diagnostic and treatment capacity.</p><p>Additionally, the Government published the Major Conditions Strategy Case for Change and Our Strategic Framework on 14 August 2023, which sets out our approach to making the choices over the next five years that will deliver the most value in facing the health challenges of today, and of the decades ahead, including for cancer.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 07/03/2024 14:06:35 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4131 label Biography information for Jim Shannon

1693015

	registered interest
	date	01/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Gastrointestinal Cancer: Diagnosis
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to improve the rate of early diagnosis of (a) bowel and (b) bowel-related cancers.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	16469
	answer	answer is ministerial correction date of answer 07/03/2024 answer text <p>The Department is taking steps to improve the rate of early diagnosis for all cancers, including bowel and bowel-related cancers, and is working jointly with NHS England on implementing the delivery plan, for tackling the COVID-19 related backlogs in elective care. This includes plans to spend more than £8 billion from 2022/23 to 2024/25 to help drive up and protect elective activity, including cancer diagnosis and treatment.</p><p>NHS England is working to meet the Faster Diagnosis Standard, which sets a target of 28 days from urgent referral by a general practitioner or screening programme to patients being told that they have cancer, or that cancer is ruled out. To achieve this target NHS England has: streamlined bowel cancer pathways by implementing faecal immunochemical testing triage for patients in primary and secondary care settings on a suspected cancer pathway; implemented non-symptom specific pathways for patients who present with non-specific symptoms, or combinations of non-specific symptoms, that can indicate several different cancers; and has opened community diagnostic centres across England, expanding diagnostic capacity and by prioritising this capacity for cancer services.</p><p>In 2023 the NHS England’s Help Us Help You campaign urged people to take up the offer of bowel screening when invited, and the screening offer for the bowel screening programme is being gradually extended from age 60 down to 50 years old by 2025, ensuring more people are screened and potentially diagnosed with bowel cancer at the earliest stage.  The National Health Service is also now offering routine preventative bowel cancer screening to thousands of people in England with a genetic condition, Lynch syndrome, that increases their chance of developing bowel cancer and other certain other cancers. This gives the NHS a better chance of finding cancers at a time when they can be more easily and effectively treated.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 07/03/2024 14:13:52 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4131 label Biography information for Jim Shannon

1693016

	registered interest
	date	01/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Gastrointestinal Cancer: Diagnosis
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to ensure that people with lower gastrointestinal cancers are diagnosed in line with the faster diagnosis standard.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	16470
	answer	answer is ministerial correction date of answer 07/03/2024 answer text <p>The Department is taking steps to achieve the Faster Diagnosis Standard (FDS), which aims to ensure people with cancer or suspected cancer, including lower gastrointestinal (GI) cancers, are diagnosed or have cancer ruled out within 28 days of referral. The Department is working jointly with NHS England on implementing the delivery plan for tackling the COVID-19 related backlogs in elective care, which includes plans to spend more than £8 billion from 2022/23 to 2024/25 to help drive up and protect elective activity, including cancer diagnosis and treatment.</p><p>To achieve the FDS target specifically, NHS England have implemented a timed pathway for lower GI cancer, by requiring faecal immunochemical testing (FIT) for patients in primary and secondary care settings on a suspected lower GI cancer pathway. FIT testing prevents patients from having unnecessary colonoscopies, freeing up capacity for these procedures, and ensuring the most urgent symptomatic patients are seen more quickly. Across 2022/2023, the proportion of lower GI referrals with a related FIT test rose from 24% to 69%.</p><p>NHS England is also implementing non symptom specific pathways (NSS) for patients who present with non-specific symptoms or combinations of non-specific symptoms that can indicate several different cancers, including symptoms that may indicate lower GI cancers.</p><p>In addition, at the 2021 Spending Review the Government awarded £2.3 billion to transform diagnostic services from 2022 to 2025, most of which will help increase the number of community diagnostic centres (CDCs) up to 160 by March 2025, prioritising CDCs for cancer services. General practice teams have also been given direct access to tests like computed tomography scans, magnetic resonance imaging, and ultrasounds helping to cut waiting times and speed up the diagnosis of, or ruling out of, cancer. This funding is also being used to expand endoscopy capacity within acute settings, and in CDCs.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 07/03/2024 14:20:55 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4131 label Biography information for Jim Shannon

1691590

	registered interest
	date	26/02/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Blood Cancer: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how long her Department has been aware of issues associated with health technology appraisal of combination medicines for blood cancers; and whether her Department is giving additional resources to (a) NICE and (b) NHS England to tackle those issues.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	15636
	answer	answer is ministerial correction date of answer 07/03/2024 answer text <p>The Competition and Markets Authority (CMA) published a statement in November 2023 that clarifies the circumstances under which it will not prioritise enforcement action against drug firms when they implement a specific negotiation framework, to make more combination therapies available on the National Health Service. The statement is available at the following link:</p><p><a href="https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Furlsand.esvalabs.com%2F%3Fu%3Dhttps%253A%252F%252Fwww.gov.uk%252Fgovernment%252Fpublications%252Fcombination-therapies-prioritisation-statement%26e%3D9f250c40%26h%3D982fc74b%26f%3Dy%26p%3Dn&amp;data=05%7C02%7CMD.Support%40dhsc.gov.uk%7C6895e030137048b2a9a008dc390f1db9%7C61278c3091a84c318c1fef4de8973a1c%7C1%7C0%7C638447984280723763%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&amp;sdata=lSHVnGx%2F65WBcfRomJ9%2FCoXfj2Yv%2FdpftPZohJ8ixl8%3D&amp;reserved=0" target="_blank">https://www.gov.uk/government/publications/combination-therapies-prioritisation-statement</a></p><p>In the 2024 Voluntary Scheme for Branded Medicines Pricing, Access and Growth, NHS England committed to launching a consultation on updating the NHS England Commercial Framework for New Medicines, by July of this year. This consultation will reflect the CMA’s statement, and will be used to consider options for transacting a solution for some combination therapies, under specific circumstances.</p><p>The National Institute for Health and Care Excellence (NICE) also gave specific consideration to the evaluation of combination therapies in the comprehensive review of its methods and processes for health technology evaluation, that concluded in January 2022. The NICE’s published health technology evaluation manual describes the considerations that will be given to the evaluation of combination therapies where relevant.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 15637 question first answered 07/03/2024 16:36:41 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4131 label Biography information for Jim Shannon